Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

President-elect Donald Trump has announced he wants to appoint vaccine sceptic Robert F Kennedy Jr as the head of the US ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Liquidia's collaboration on L606 boosts long-term growth potential. Find out why LQDA stock’s valuation and upcoming launches ...

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...